Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SRPT vs IONS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRPT Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

SRPT Overall Winner 6-Pillar Tally: SRPT 3 – 3 IONS Matrix Metrics: SRPT 6 – 4 IONS

As of Nov 16, 2026, Sarepta Therapeutics,, Inc. (SRPT) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SRPT carries a Unified Composite Score of 37.8/100 (SELL) at $15.14 (10.8x Forward P/E, -0.4% operating margin), whereas IONS carries 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin).

  • Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. SRPT 37.8/100 SELL), SRPT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-0.4% vs. -58.8% operating margin) and revenue trajectory (-4.5% vs. +54.9% YoY).
  • Technical & Structure Timing Caution: SRPT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.0); meanwhile IONS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRPT vs IONS
SRPT NASDAQ Head-to-Head Winner
Sarepta Therapeutics,, Inc. Common Stock
Pharmaceutical Preparations
$15.14
-5.76% 1D
Market Cap $1.7B
TTM Revenue $1.96B
Forward P/E 10.8x
Beta / 30D Vol 1.47β · 58% Vol
Unified Composite Score
37.8 / 100 SELL
Tech 32.0 Fund 51.0 Flow 71.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.9%), weak momentum, RSI 33
RSI-14: 33.0 · SMA20: $17.82 · SMA50: $18.44
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
TTM Revenue $960M
Forward P/E 90.9x
Beta / 30D Vol 0.18β · 86% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.3%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $38.46 · SMA50: $43.07

6-Pillar Scorecard Institutional Category Breakdown (SRPT 3 – 3 IONS)

Columns: Metric · SRPT · IONS
1. Valuation Multiples SRPT
Forward P/E 10.8x 90.9x
Trailing P/E N/M 90.9x
PEG Ratio N/M N/M
EV / Revenue 1.2x 6.2x
2. Growth & Scale IONS
Revenue Growth (YoY) -4.5% +54.9%
Earnings Growth (YoY) N/A -43.7%
TTM Revenue (USD) $1.96B $960M
Market Cap $1.7B $4.7B
3. Profitability & Quality SRPT
Gross Margin 23.4% 3.0%
Operating Margin -0.4% -58.8%
Net Profit Margin -5.9% -56.9%
Return on Equity (ROE) -8.1% -108.0%
4. Balance Sheet & Cash Flow SRPT
Cash Generation (TTM) $172M -$623M
Cash Flow Margin 8.8% -64.9%
Net Cash / Leverage $580M Net Debt (0.69x D/E) $1.33B Net Debt (4.14x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IONS
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 54.5% (7th %ile) 59.9% (17th %ile)
Put/Call OI Skew 0.66x (Call-Skewed) 1.81x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat IONS
OpEx & R&D Intensity 23.8% of Rev ($466M) 61.8% of Rev ($593M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRPT (6) vs IONS (4)
Institutional Metric SRPT IONS Criterion Row Edge
Market Capitalization
Scale
$1.7B $4.7B Larger Scale IONS
Trailing P/E Ratio
Valuation
N/M 90.9x Lower Multiple IONS
Forward P/E Ratio
Valuation
10.8x 90.9x Lower Multiple SRPT
Revenue Growth (YoY)
Growth
-4.5% +54.9% Higher Growth IONS
Operating Margin (TTM)
Profitability
-0.4% -58.8% Higher Margin SRPT
Net Profit Margin
Profitability
-5.9% -56.9% Higher Margin SRPT
Return on Equity (ROE)
Capital Efficiency
-8.1% -108.0% Higher ROE SRPT
52-Week Range Position
Momentum
5% ($15–$25) 2% ($27–$87) Stronger Trend SRPT
Beta / 30D Volatility
Risk Regime
1.47β · 58% Vol 0.18β · 86% Vol Lower Realized Risk SRPT
Unified Institutional Score
Composite Signal
37.8 / 100 (SELL) 63.9 / 100 (BUY) Higher Composite IONS
Trailing 12M Revenue (USD)
Operating Scale
$1.96B $960M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.4% 3.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.2x EV/Rev N/M PEG · 6.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$172M ($580M Net Debt (0.69x D/E)) -$623M ($1.33B Net Debt (4.14x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRPT +22.04 pp
SRPT: -11.44% · IONS: -33.48%
3M Horizon SRPT +36.13 pp
SRPT: -15.96% · IONS: -52.09%
6M Horizon SRPT +49.64 pp
SRPT: -10.97% · IONS: -60.61%
1Y Horizon SRPT +44.08 pp
SRPT: -15.02% · IONS: -59.1%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SRPT Revenue IONS Revenue SRPT Op. Margin IONS Op. Margin Margin Leader
FY2018 $300M $600M -114.1% -10.2% IONS
FY2019 $380M $1.12B -185.3% 32.6% IONS
FY2020 $460M $730M -123.8% -23.6% IONS
FY2021 $610M $810M -75.1% -3.7% IONS
FY2022 $840M $590M -63.5% -69.8% SRPT
FY2023 $1.14B $790M -23.4% -44.9% SRPT
FY2024 $1.79B $710M 12.2% -67.4% SRPT
FY2025 $1.86B $940M -37.5% -40.4% SRPT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRPT BREAKDOWN
52d in phase · OBV DISTRIBUTION
Current IV 54.5%
IV Percentile 7th %ile
Put/Call OI Skew 0.66x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SRPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IONS BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 17th %ile
Put/Call OI Skew 1.81x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IONS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRPT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -0.4% operating margin.
OpEx & R&D Reinvestment 23.8% of Rev ($466M)
90D Engineering Disclosures 0 Published
IONS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment 61.8% of Rev ($593M)
90D Engineering Disclosures 0 Published

Investor FAQ SRPT vs IONS Key Questions & Quantitative Answers

As of Nov 16, 2026, Sarepta Therapeutics,, Inc. (SRPT) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SRPT carries a Unified Composite Score of 37.8/100 (SELL) at $15.14 (10.8x Forward P/E, -0.4% operating margin), whereas IONS carries 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin). Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. SRPT 37.8/100 SELL), SRPT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-0.4% vs. -58.8% operating margin) and revenue trajectory (-4.5% vs. +54.9% YoY). Technical & Structure Timing Caution: SRPT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.0); meanwhile IONS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IONS leads the Growth & Scale pillar: SRPT posts -4.5% YoY revenue growth and N/A YoY earnings growth on $1.96B TTM revenue (23.4% gross margin, -0.4% operating margin), compared with IONS at +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SRPT cumulative revenue shifted +520.0% while IONS shifted +56.7%. In operating R&D and SG&A reinvestment, SRPT deploys 23.8% of Rev ($466M) (0 90-day corporate R&D disclosures) versus 61.8% of Rev ($593M) (0 disclosures) for IONS.

SRPT screens cheaper on headline valuation multiples. SRPT trades at 10.8x Forward P/E, N/M Trailing P/E, N/M PEG, and 1.2x EV/Revenue (8.8% FCF margin), whereas IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRPT (-8.1% ROE) versus IONS (-108.0% ROE) capital efficiency.

In options market volatility and institutional positioning, SRPT carries 54.5% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.66x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.47β · 58% Vol realized risk). By comparison, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.